NASDAQ
33.08USD
+1.24 (+3.89%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2B
P/E
—
EPS
—
Beta
0.59
52W range
22.24-46
Day range
31.83–33.77
Open
32.00
Prev close
31.84
Volume
833.2K
Avg volume
1.1M
Dividend
0.00
IPO
2013-07-24
https://www.marketbeat.com/instant-alerts/agios-pharmaceuticals-touts-mitapivat-gains-despite-sickle-cell-pain-miss-2026-06-13/ · 6/13/2026+0.60
https://www.globenewswire.com/news-release/2026/06/13/3311392/31990/en/Agios-Showcases-RISE-UP-Phase-3-Results-at-EHA-2026-Plenary-Session-Reinforcing-Strong-Anti-Hemolytic-Profile-of-Mitapivat-in-Sickle-Cell-Disease.html · 6/13/2026+0.60
https://www.fool.com/investing/2026/05/02/heres-why-shares-in-agios-pharmaceuticals-soared-t/ · 5/2/2026+0.60
https://www.prnewswire.com/news-releases/lost-money-on-agios-pharmaceuticals-incagio-contact-levi--korsinsky-regarding-an-ongoing-investigation-302710578.html · 3/11/2026-1.00
https://www.fool.com/coverage/filings/2026/02/17/agios-stock-down-16-in-a-year-as-fund-cuts-stake-by-usd5-6-million-after-50-november-crash/ · 2/17/2026-0.80
https://www.investors.com/news/technology/biotech-stocks-2026-mergers-obesity-drugs/ · 1/8/2026-0.80
https://seekingalpha.com/article/4855621-agios-pharmaceuticals-inc-agio-discusses-fda-approval-of-aqvesme-for-anemia-in-alpha-and-beta · 12/24/2025+1.00
https://www.globenewswire.com/news-release/2025/11/03/3179391/31990/en/Agios-to-Present-New-Mitapivat-Data-in-Rare-Blood-Disorders-at-67th-ASH-Annual-Meeting-and-Exposition.html · 11/3/2025+0.60
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-agios-pharmaceuticals-inc--agio-302578939.html · 10/8/2025-1.00
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-agios-pharmaceuticals-inc--agio-302567924.html · 9/28/2025-0.80
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-agios-pharmaceuticals-inc--agio-302558727.html · 9/18/2025-0.80
https://www.prnewswire.com/news-releases/agio-investors-have-opportunity-to-join-agios-pharmaceuticals-inc-fraud-investigation-with-the-schall-law-firm-302560089.html · 9/18/2025-1.00
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
